FDA Panel Flags Insufficient Data for Chronic Cough Drug

Advisers to the FDA said that data on Merck's chronic cough drug do not provide sufficient evidence to prove its clinical benefit for patients.

Related Keywords

Bengaluru ,Karnataka ,India ,Khushi Mandowara ,Emma Dagostino ,Christy Santhosh ,Shounak Dasgupta ,Reuters ,Cystic Fibrosis Foundation ,Drug Administration ,Emmad Agostino ,Patient Safety ,Otolaryngology ,Nt Specialty ,Ead And Neck Surgery Ent Speciality ,Chronic Cough ,Drug Development ,Drug Discovery ,Drug Pipeline ,Drug Development Pipeline ,Experimental Drug ,Cough ,Russis ,Adverse Effects ,Side Effects ,Cystic Fibrosis ,Us Food And Drug Administration ,Nited States Food And Drug Administration ,Fda ,Refractory ,